(Q92266883)

English

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

scientific article published on 29 July 2019

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

author name string

Joon Ho Moon

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Sang Kyun Sohn

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Seok Jin Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Sung-Hoon Jung

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Je-Jung Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Ho-Jin Shin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Won Sik Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Sung Hwa Bae

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Min Kyoung Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Ho Sup Lee

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Kihyun Kim

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Chang-Ki Min

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Korean Multiple Myeloma Working Party

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

publication date

29 July 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

54

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

2051-2059

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

CR represents an early index of potential long survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat multiple myeloma in younger patients

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0629-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/S41409-019-0629-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31358918%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q92266883&oldid=1763047917"